Shattuck Labs

Shattuck Labs Gross Margin

The Gross Margin of Shattuck Labs (STTK) as of Nov 16, 2026 is -195.10 %. In the previous year, Gross Margin was 14.46 % — a change of -1,449.66% (lower).

Gross Margin

-195.10 %

YoY

-1,449.66%

Last updated:

Gross Margin of Shattuck Labs is 2025 -195.10 % . Gross Margin of Shattuck Labs was 2024 14.46 % . It decreases by -1,449.66% lower compared to the previous year.

For Shattuck Labs, the gross margin of -195.1% is down versus 95.4% a few years ago.

The Shattuck Labs Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
-10.54 USD
Jan 1, 2019
-195.52 USD
Jan 1, 2020
100.00 USD
Jan 1, 2021
95.40 USD
Jan 1, 2022
100.00 USD
Jan 1, 2023
-143.93 USD
Jan 1, 2024
14.46 USD
Jan 1, 2025
-195.10 USD
The Shattuck Labs Gross Margin history
YEARGross MarginYoY
-195.10 %-1,449.66%
14.46 %-110.04%
-143.93 %-243.93%
100.00 %+4.82%
95.40 %-4.60%
100.00 %-151.15%
-195.52 %+1,755.33%
-10.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shattuck Labs Stock analysis

What does Shattuck Labs do? Shattuck Labs, Inc. develops dual-sided fusion proteins for cancer and autoimmune disease treatment, focusing on bi-functional fusion proteins as a new class of biologic medicine. Its lead product candidate, SL-172154, is in Phase I clinical trials for ovarian cancer and hematologic malignancies like acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS). The company also advances the GADLEN platform, a Gamma Delta T Cell Engager designed to bridge gamma delta T cells to tumor antigens for cancer treatment. Shattuck Labs generates revenue through the development and clinical trials of these innovative therapies, targeting patients with cancer and autoimmune diseases. The firm's primary products are SL-172154 and the GADLEN platform, with SL-172154 currently in Phase I trials for ovarian cancer and hematologic malignancies. These therapies are developed for patients with cancer and autoimmune diseases, aiming to induce antitumor immune responses. The company's focus on bi-functional fusion proteins positions it as a leader in novel biologic medicine development for targeted treatment approaches. Shattuck Labs' business model centers on the research, development, and clinical testing of its proprietary fusion protein therapies. The company's revenue streams are derived from the progression of its clinical trials and potential future commercialization of its products. By advancing SL-172154 and the GADLEN platform, Shattuck Labs targets the high-value markets of cancer and autoimmune disease treatment, leveraging its innovative fusion protein technology to address unmet medical needs. Shattuck Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shattuck Labs stock

Gross Margin of Shattuck Labs is -195.10 % in 2025.

Gross Margin of Shattuck Labs changed from 14.46 % to -195.10 %, representing a -1,449.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Shattuck Labs since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Shattuck Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Shattuck Labs

All Key Metrics — Shattuck Labs